| 臺大學術典藏 |
2022-05-09T08:46:30Z |
Diabetes mellitus, superoxide dismutase and peroxisome proliferator activated receptor gamma polymorphisms modify the outcome of end-stage renal disease patients of Han Chinese origin
|
Chao C.-T.; Huang J.-W.; Chiang C.-K.; YEN-CHING CHEN; Fang C.-C.; Hu F.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-04-26T01:30:37Z |
The effects of measurement site and ambient temperature on body temperature values in healthy older adults: A cross-sectional comparative study
|
Lu S.-H.; YU-TZU DAI; Yen C.-J. |
| 臺大學術典藏 |
2022-04-26T01:30:35Z |
Shared risk factors for distinct geriatric syndromes in older Taiwanese inpatients
|
Chen C.C.-H.; YU-TZU DAI; Yen C.-J.; Huang G.-H.; Wang C. |
| 臺大學術典藏 |
2022-04-26T01:30:34Z |
Prevalence of geriatric conditions: A hospital-wide survey of 455 geriatric inpatients in a tertiary medical center
|
Chen C.C.H.; Yen C.-J.; YU-TZU DAI; Wang C.; Huang G.-H. |
| 臺大學術典藏 |
2022-04-26T01:30:32Z |
Effect of age on febrile response in patients with healthcare-associated bloodstream infection
|
Lu S.-H.; Chen Y.-C.; Chang Y.-C.; Yen C.-J.; YU-TZU DAI |
| 臺大學術典藏 |
2022-04-15T06:39:33Z |
Shared risk factors for distinct geriatric syndromes in older Taiwanese inpatients
|
CHERYL CHIA-HUI CHEN; Dai Y.-T.; Yen C.-J.; Huang G.-H.; Wang C. |
| 臺大學術典藏 |
2022-04-15T06:39:32Z |
Modified hospital elder life program: Effects on abdominal surgery patients
|
CHERYL CHIA-HUI CHEN; Lin M.-T.; Tien Y.-W.; Yen C.-J.; Huang G.-H.; Inouye S.K. |
| 臺大學術典藏 |
2022-04-15T06:39:31Z |
Prevalence of geriatric conditions: A hospital-wide survey of 455 geriatric inpatients in a tertiary medical center
|
CHERYL CHIA-HUI CHEN; Yen C.-J.; Dai Y.-T.; Wang C.; Huang G.-H. |
| 臺大學術典藏 |
2022-04-15T06:39:26Z |
Pre-surgical Geriatric Syndromes, Frailty, and Risks for Postoperative Delirium in Older Patients Undergoing Gastrointestinal Surgery: Prevalence and Red Flags
|
CHERYL CHIA-HUI CHEN; Lin M.-T.; Liang J.-T.; Chen C.-M.; Yen C.-J.; Huang G.-H. |
| 臺大學術典藏 |
2022-03-31T02:39:37Z |
Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients
|
Kao T.-W.; Huang J.-W.; Hung K.-Y.; Chang Y.-Y.; PAU-CHUNG CHEN; Yen C.-J.; Chen Y.-M.; Chu T.-S.; Wu M.-S.; Tsai T.-J.; Wu K.-D.; Wang J.-D. |
| 臺大學術典藏 |
2022-03-09T03:12:31Z |
Citrobacter peritoneal dialysis peritonitis: Rare occurrence with poor outcomes
|
Chao C.-T.; Lee S.-Y.; Yang W.-S.; HUEI-WEN CHEN; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2022-03-09T03:12:31Z |
Peritoneal dialysis peritonitis by anaerobic pathogens: A retrospective case series
|
Chao C.-T.; Lee S.-Y.; Yang W.-S.; HUEI-WEN CHEN; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2022-03-09T03:12:28Z |
Acinetobacter peritoneal dialysis peritonitis: A changing landscape over time
|
Chao C.-T.; Lee S.-Y.; Yang W.-S.; HUEI-WEN CHEN; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2022-03-09T03:12:27Z |
Viridans streptococci in peritoneal dialysis peritonitis: Clinical courses and long-term outcomes
|
Chao C.-T.; Lee S.-Y.; Yang W.-S.; HUEI-WEN CHEN; Fang C.-C.; Yen C.-J.; Chiang C.-K.; Hung K.-Y.; Huang J.-W. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients�� experience within a population-based study
|
Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-07T07:05:51Z |
High peritoneal KT/V and peritonitis rates are associated with peritoneal calcification.
|
Huang J.W.; Lien Y.C.; Yang C.Y.; Liu K.L.; Fang C.C.; Wu C.K.; JEN-KUANG LEE; Wu H.Y.; Chiang C.K.; Cheng H.T.; Yen C.J.; Hung K.Y. |
| 臺大學術典藏 |
2022-03-07T07:05:48Z |
Osteoprotegerin, inflammation and dyslipidemia are associated with abdominal aortic calcification in non-diabetic patients on peritoneal dialysis
|
Huang J.-W.; Lien Y.-C.; Yang C.-Y.; Liu K.-L.; Wu C.-F.; Yen C.-J.; Wu C.-K.; JEN-KUANG LEE; Ho S.-R.; Wu H.-Y.; Chiang C.-K.; Cheng H.-T.; Shyu R.-S.; Hung K.-Y. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 國立成功大學 |
2022 |
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
|
Chen, Chen C.-T.;Feng, Y.-H.;Yen, C.-J.;Chen, S.-C.;Lin, Y.-T.;Lu, Lu L.-C.;Hsu, C.-H.;Cheng, A.-L.;Shao, Y.-Y. |
| 國立成功大學 |
2022 |
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study: RAM/PL + BSC for advanced HCC
|
Shao, G.;Bai, Y.;Yuan, X.;Chen, X.;Gu, S.;Gu, K.;Hu, C.;Liang, H.;Guo, Y.;Wang, J.;Yen, C.-J.;Lee, V.H.-F.;Wang, C.;Widau, R.C.;Zhang, W.;Liu, J.;Zhang, Q.;Qin, S. |
| 國立成功大學 |
2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, T.-J.;Yang, S.-H.;Chiu, S.-C.;Hsueh, S.-W.;Chiang, N.-J.;Li, C.-P.;Bai, L.-Y.;Cheng, F.-M.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Su, Y.-Y.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2022 |
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
|
Simonelli, M.;Garralda, E.;Eskens, F.;Gil-Martin, Martin M.;Yen, C.-J.;Obermannova, R.;Chao, Y.;Lonardi, S.;Melichar, B.;Moreno, V.;Yu, M.-L.;Bongiovanni, A.;Calvo, E.;Rottey, S.;Machiels, J.-P.;Gonzalez-Martin, A.;Paz-Ares, L.;Chang, Chang C.-L.;Mason, W.;Lin, C.-C.;Reardon, D.A.;Vieito, M.;Santoro, A.;Meng, R.;Abbadessa, G.;Menas, F.;Lee, H.;Liu, Q.;Combeau, Combeau C.;Ternes, N.;Ziti-Ljajic, S.;Massard, C. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
